Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 8, 2015, Pages 1983-1990

  Borggren, Marie ^a   Nielsen, Jens ^a   Bragstad, Karoline ^a   Karlsson, Ingrid ^a   Krog, Jesper S ^b   Williams, James A ^c   Fomsgaard, Anders ^a,d  

^a STATENS SERUM INSTITUT   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c NATURE TECHNOLOGY CORPORATION   (United States)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

DNA vaccine; Influenza; Needle free; NTC8385 VA1; NTC9385R; Polyvalent

Indexed keywords

DNA VACCINE; HYPNORM; INFLUENZA VACCINE; KANAMYCIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; DRUG DELIVERY SYSTEM; ELECTROPORATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEMAGGLUTINATION INHIBITION TEST; HUMAN; MASS IMMUNIZATION; NEEDLE FREE DELIVERY; NONHUMAN; PIG; RABBIT; ANIMAL; BLOOD; CUTANEOUS DRUG ADMINISTRATION; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; SWINE DISEASES; VETERINARY;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIBODIES, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; RABBITS; SWINE; SWINE DISEASES; VACCINES, DNA;

EID: 84944449690     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1011987     Document Type: Article

References (57)

1. Liu MA. DNA vaccines: An historical perspective and view to the future. Immunol Rev 2011; 239:62-84; PMID:21198665; http://dx. doi. org/10. 1111/j. 1600- 065X. 2010. 00980. x
2. Kutzler MA, Weiner DB. DNA vaccines: Ready for prime time? Nat Rev Genet 2008; 9:776-88; PMID:18781156; http://dx. doi. org/10. 1038/nrg2432
3. Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev 2013; 26:476-92; PMID:23824369; http://dx. doi. org/10. 1128/CMR. 00097-12
4. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010; 363:2036-44; PMID:21083388; http://dx. doi. org/10. 1056/NEJMra 1002842
5. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356:152-4; PMID:1545867; http://dx. doi. org/10. 1038/356152a0
6. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247:1465-8; PMID:1690918; http://dx. doi. org/10. 1126/science. 1690918
7. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9; PMID:8456302; http://dx. doi. org/10. 1126/science. 8456302
8. Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993; 11:957-60; PMID:8212843; http://dx. doi. org/10. 1016/0264-410X(93)90385-B
9. Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, Mant T, Nolan A, Zambon M, Ellis J, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009; 27:2506-12; PMID:19368793; http://dx. doi. org/10. 1016/j. vaccine. 2009. 02. 061
10. Girard MP, Tam JS, Pervikov Y, Katz JM. Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Hong Kong SAR, China, 24-26 January 2013. Vaccine 2013; 31:3766-71; PMID:23810374; http://dx. doi. org/ 10. 1016/j. vaccine. 2013. 06. 047
11. Smith LR, Wloch MK, Ye M, Reyes LR, Boutsaboualoy S, Dunne CE, Chaplin JA, Rusalov D, Rolland AP, Fisher CL, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28:2565-72; PMID:20117262; http://dx. doi. org/10. 1016/j. vaccine. 2010. 01. 029
12. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, Hendel CS, McTamney PM, Pearce MB, Yassine HM, Boyington JC, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11:916- 24; PMID:21975270; http://dx. doi. org/10. 1016/ S1473-3099(11)70240-7
13. Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Pearce MB, Tumpey TM, Koup RA, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012; 19:1792-7; PMID:22956656; http://dx. doi. org/ 10. 1128/CVI. 05663-11
14. Corbet S, Vinner L, Hougaard DM, Bryder K, Nielsen HV, Nielsen C, Fomsgaard A. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons. AIDS Res Hum Retroviruses 2000; 16:1997-2008; PMID:11153083; http://dx. doi. org/10. 1089/ 088922200750054738
15. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol 2012; 162:171-82; PMID:22981627; http://dx. doi. org/10. 1016/j. jbiotec. 2012. 08. 012
16. Williams JA. Vector design for improved DNA vaccine efficacy, safety and production. Vaccines 2013; 1:225- 49; http://dx. doi. org/10. 3390/vaccines1030225
17. Shan S, Jiang Y, Bu Z, Ellis T, Zeng X, Edwards J, Tian G, Li Y, Ge J, Chen H, et al. Strategies for improving the efficacy of a H6 subtype avian influenza DNA vaccine in chickens. J Virol Methods 2011; 173:220-6; PMID:21333689; http://dx. doi. org/10. 1016/j. jviromet. 2011. 02. 008
18. Li J, Jiang Y, Zhao S, Chang X, Liu J, Zeng X, Li Y, Chen H. Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail. Avian Dis 2012; 56:937-9; PMID:23402115; http:// dx. doi. org/10. 1637/10150-040812-ResNote. 1
19. Patel A, Dong JC, Trost B, Richardson JS, Tohme S, Babiuk S, Kusalik A, Kung SK, Kobinger GP. Pentamers not found in the universal proteome can enhance antigen specific immune responses and adjuvant vaccines. PLoS One 2012; 7:e43802; PMID:22937099; http://dx. doi. org/10. 1371/journal. pone. 0043802
20. Wang S, Hackett A, Jia N, Zhang C, Zhang L, Parker C, Zhou A, Li J, Cao WC, Huang Z, et al. Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One 2011; 6:e28757; PMID:22205966; http://dx. doi. org/ 10. 1371/journal. pone. 0028757
21. Ault A, Zajac AM, Kong WP, Gorres JP, Royals M, Wei CJ, Bao S, Yang ZY, Reedy SE, Sturgill TL, et al. Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies. Vaccine 2012; 30:3965-74; PMID:22449425; http://dx. doi. org/10. 1016/j. vaccine. 2012. 03. 026
22. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J, O'Hagan D, Donnelly J, Widera G, Rabussay D, et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004; 22:2489-93; PMID:15193413; http://dx. doi. org/ 10. 1016/j. vaccine. 2003. 11. 073
23. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164:4635-40; PMID:10779767; http://dx. doi. org/10. 4049/jimmunol. 164. 9. 4635
24. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia- Akli R, Weiner DB. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008; 26:440-8; PMID:18082294; http://dx. doi. org/10. 1016/j. vaccine. 2007. 10. 041
25. Bragstad K, Vinner L, Hansen MS, Nielsen J, Fomsgaard A. A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A(H1N1)pdm09 virus infection. Vaccine 2013; 31:2281-8; PMID:23499598; http://dx. doi. org/ 10. 1016/j. vaccine. 2013. 02. 061
26. van Drunen Littel-van den Hurk S, Babiuk SL, Babiuk LA. Strategies for improved formulation and delivery of DNA vaccines to veterinary target species. Immunol Rev 2004; 199:113-25; PMID:15233730; http://dx. doi. org/10. 1111/j. 0105-2896. 2004. 00140. x
27. Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008; 26:2100-10; PMID:18378365; http://dx. doi. org/10. 1016/j. vaccine. 2008. 02. 033
28. Yager EJ, Dean HJ, Fuller DH. Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Rev Vaccines 2009; 8:1205-20; PMID:19722894; http://dx. doi. org/10. 1586/erv. 09. 82
29. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006; 24:4475-81; PMID:16150518; http://dx. doi. org/10. 1016/j. vaccine. 2005. 08. 012
30. McAllister L, Anderson J, Werth K, Cho I, Copeland K, Le Cam Bouveret N, Plant D, Mendelman PM, Cobb DK. Needle-free jet injection for administration of influenza vaccine: A randomised non-inferiority trial. Lancet 2014; 384:674-81; PMID:24881803; http://dx. doi. org/10. 1016/S0140-6736(14)60524-9
31. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 2006; 5:543-8; PMID:16816837
32. Gorres JP, Lager KM, Kong WP, Royals M, Todd JP, Vincent AL, Wei CJ, Loving CL, Zanella EL, Janke B, et al. DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs. Clin Vaccine Immunol 2011; 18:1987- 95; PMID:21918118; http://dx. doi. org/10. 1128/ CVI. 05171-11
33. Martelli P, Cordioli P, Alborali LG, Gozio S, De Angelis E, Ferrari L, Lombardi G, Borghetti P. Protection and immune response in pigs intradermally vaccinated against porcine reproductive and respiratory syndrome (PRRS) and subsequently exposed to a heterologous European (Italian cluster) field strain. Vaccine 2007; 25:3400-8; PMID:17276558; http://dx. doi. org/ 10. 1016/j. vaccine. 2006. 12. 050
34. Ferrari L, Borghetti P, Gozio S, De Angelis E, Ballotta L, Smeets J, Blanchaert A, Martelli P. Evaluation of the immune response induced by intradermal vaccination by using a needle-less system in comparison with the intramuscular route in conventional pigs. Res Vet Sci 2011; 90:64-71; PMID:20546827; http://dx. doi. org/ 10. 1016/j. rvsc. 2010. 04. 026
35. Martelli P, Saleri R, Cavalli V, De Angelis E, Ferrari L, Benetti M, Ferrarini G, Merialdi G, Borghetti P. Systemic and local immune response in pigs intradermally and intramuscularly injected with inactivated Mycoplasma hyopneumoniae vaccines. Vet Microbiol 2014; 168:357-64; PMID:24332702; http://dx. doi. org/ 10. 1016/j. vetmic. 2013. 11. 025
36. Tassis PD, Papatsiros VG, Nell T, Maes D, Alexopoulos C, Kyriakis SC, Tzika ED. Clinical evaluation of intradermal vaccination against porcine enzootic pneumonia (Mycoplasma hyopneumoniae). Vet Record 2012; 170:261; PMID:22262700; http://dx. doi. org/ 10. 1136/vr. 100239
37. Bragstad K, Martel CJ, Thomsen JS, Jensen KL, Nielsen LP, Aasted B, Fomsgaard A. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades. Influenza Other Respir Viruses 2011; 5:13-23; PMID:21138536; http://dx. doi. org/10. 1111/j. 1750-2659. 2010. 00177. x
38. Luke JM, Vincent JM, Du SX, Gerdemann U, Leen AM, Whalen RG, Hodgson CP, Williams JA. Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers. Gene Ther 2011; 18:334-43; PMID:21107439; http://dx. doi. org/10. 1038/gt. 2010. 149
39. Carnes AEW, J. A. Process for plasmid DNA fermentation. US Patent 7943377 2011
40. Medi BM, Hoselton S, Marepalli RB, Singh J. Skin targeted DNA vaccine delivery using electroporation in rabbits. I: efficacy. Int J Pharm 2005; 294:53-63; PMID:15814230; http://dx. doi. org/10. 1016/j. ijpharm. 2004. 12. 014
41. Medi BM, Singh J. Skin targeted DNA vaccine delivery using electroporation in rabbits II. Safety. Int J Pharm 2006; 308:61-8; http://dx. doi. org/10. 1016/j. ijpharm. 2005. 10. 035
42. Borggren M, Vinner L, Andresen BS, Grevstad B, Repits J, Melchers M, Elvang T, Sanders RW, Martinon F, Dereuddre-Bosquet N, et al. Optimization of HIV-1 envelope DNA vaccine candidates within three different animal models, guinea pigs, rabbits and cynomolgus macaques. Vaccines 2013; 1:305-27; http://dx. doi. org/10. 3390/vaccines1030305
43. Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, et al. Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model. PLoS One 2013; 8:e74552
44. WHO Recommendations for Influenza Vaccine Composition [http://www. who. int/influenza/vaccines/virus/en/
45. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutinationinhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010; 10:18; PMID:20210985; http://dx. doi. org/10. 1186/ 1471-2288-10-18
46. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:1879-85; PMID:21998477; http://dx. doi. org/10. 1093/infdis/jir661
47. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Japan J Infect Dis 2005; 58:195-207; PMID:16116250
48. Pillet S, Kobasa D, Meunier I, GrayM, Laddy D, Weiner DB, von Messling V, Kobinger GP. Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine 2011; 29:6793-801; PMID:21211587; http:// dx. doi. org/10. 1016/j. vaccine. 2010. 12. 059
49. Xu K, Ling ZY, Sun L, Xu Y, Bian C, He Y, Lu W, Chen Z, Sun B. Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol 2011; 24:45-56; PMID:21319978; http://dx. doi. org/ 10. 1089/vim. 2010. 0056
50. Choi YK, Goyal SM, Joo HS. Retrospective analysis of etiologic agents associated with respiratory diseases in pigs. Can Vet J 2003; 44:735-7; PMID:14524628
51. Loeffen WL, Kamp EM, Stockhofe-Zurwieden N, van Nieuwstadt AP, Bongers JH, Hunneman WA, Elbers AR, Baars J, Nell T, van Zijderveld FG. Survey of infectious agents involved in acute respiratory disease in finishing pigs. Vet Record 1999; 145:123-9; PMID:10466829; http://dx. doi. org/10. 1136/vr. 145. 5. 123
52. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma SK, Cheung CL, Raghwani J, Bhatt S, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009; 459:1122-5; PMID:19516283; http://dx. doi. org/10. 1038/nature08182
53. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, SessionsWM, Xu X, Skepner E, Deyde V, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201; PMID:19465683; http://dx. doi. org/ 10. 1126/science. 1176225
54. Crisci E, Mussa T, Fraile L, Montoya M. Review: influenza virus in pigs. Mol Immunol 2013; 55:200-11; PMID:23523121; http://dx. doi. org/10. 1016/j. molimm. 2013. 02. 008
55. Holtkamp DJ, Kliebenstein JB, Neumann EJ, et al. Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers. J Swine Health Prod. 2013; 21 (2):72-84
56. (EDQM) EDftQoM. Gene Transfer Medical Products for Human Use. In European Pharmacopoeia, 7. 0 ed. Council of Europe: Strasbourg, France 2011:648
57. Agency EM. Presence of the Antibiotic Resistance Marker Gene nptII in GM Plants and Food and Feed Uses. London, UK 2007; EMEA/CVMP/56937/2007